Article in Circulation. Heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
18 authors.
Yogesh N V ReddyDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (Y.N.V.R., R.P.F., B.A.B.).ORCID 0000-0001-5322-0902
Robert P FrantzDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (Y.N.V.R., R.P.F., B.A.B.).ORCID 0000-0003-4128-3978
Paul M HassounDivision of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, MD (P.M.H., S.C.M.).ORCID 0000-0003-0601-4975
Anna HemnesDivision of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN (A.H.).ORCID 0000-0002-2755-5845
Evelyn HornPerkin Heart Failure Center, Division of Cardiology, Weill Cornell Medicine, New York, NY (E.H.).ORCID 0000-0002-5751-9415
Jane A LeopoldDivision of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (J.A.L.).ORCID 0000-0003-0598-8882
Franz RischardDivision of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Arizona, Tucson (F.R.).ORCID 0000-0002-6861-8304
Erika B RosenzweigMaria Fareri Children's Hospital and Department of Pediatrics of New York Medical College, Valhalla (E.B.R.).ORCID 0000-0003-4849-214X
Nicholas S HillDivision of Pulmonary, Critical Care, and Sleep Medicine, Tufts Medical Center, Boston, MA (N.S.H.).ORCID 0000-0002-8242-8339
Serpil C ErzurumDepartment of Cardiology, Lerner Research Institute (S.C.E.), Cleveland Clinic, OH.
Gerald J BeckDepartment of Quantitative Health Sciences (G.J.B.), Cleveland Clinic, OH.ORCID 0000-0002-8876-5045
J Emanuel FinetDepartment of Cardiovascular Medicine (J.E.F., C.L.J., W.H.W.T.), Cleveland Clinic, OH.ORCID 0000-0002-0156-6757
Christine L JellisDepartment of Cardiovascular Medicine (J.E.F., C.L.J., W.H.W.T.), Cleveland Clinic, OH.ORCID 0000-0002-8610-0533
Stephen C MathaiDivision of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, MD (P.M.H., S.C.M.).ORCID 0000-0003-3188-7209
Reena MehraDepartment of Pulmonary and Critical Care Medicine, University of Washington, Seattle (R.M.).ORCID 0000-0002-6222-2675
W H Wilson TangDepartment of Cardiovascular Medicine (J.E.F., C.L.J., W.H.W.T.), Cleveland Clinic, OH.ORCID 0000-0002-8335-735X
Barry A BorlaugDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (Y.N.V.R., R.P.F., B.A.B.).ORCID 0000-0001-9375-0596
PVDOMICS Study Group
Funding
Pulmonary Vascular Disease Phenomics Program (PVDOMICS) Data Coordinating CenterU01HL125177 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI BECK, GERALD J, ERZURUM, SERPIL C. · 2014 to 2020
$20.0M
Pulmonary Hypertension in Left Heart DiseaseR01HL162828 · NHLBI · MAYO CLINIC ROCHESTER · PI Barry A. Borlaug, Margaret M Redfield · 2023 to 2026
$3.1M
HL-Inorganic Nitrite to Enhance Benefits from Exercise Training in Heart Failure with preserved Ejection FractionR01HL128526 · NHLBI · MAYO CLINIC ROCHESTER · PI BORLAUG, BARRY A. · 2016 to 2019
$2.4M
Mayo Clinic HeartShare Clinical CenterU01HL160226 · NHLBI · MAYO CLINIC ROCHESTER · PI Barry A. Borlaug, Margaret M Redfield · 2021 to 2026
$1.8M
Intergrated Endothelial Phenotyping to Redefine Pulmonary HypertensionU01HL125215 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI LEOPOLD, JANE A, WAXMAN, AARON B · 2014 to 2018
$1.7M
PVDOMICS Defining the Future Fingerprints of Pulmonary Vascular DiseaseU01HL125218 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BERMAN-ROSENZWEIG, ERIKA S., HORN, EVELYN · 2014 to 2018
$1.6M
Redefining Pulmonary Hypertension through Pulmonary Vascular Disease Phenomics: Clinical Centers (CC) (U01).U01HL125205 · NHLBI · MAYO CLINIC ROCHESTER · PI FRANTZ, ROBERT PAUL · 2014 to 2018
$1.5M
A molecular phenotype of combined pulmonary hypertensionU01HL125212 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI HEMNES, ANNA R, NEWMAN, JOHN HUGHES · 2014 to 2018
$1.5M
Phenomic and genomic study to subphenotype Hispanics with pulmonary hypertensionU01HL125208 · NHLBI · UNIVERSITY OF ARIZONA · PI GARCIA, JOE G. N., RISCHARD, FRANZ P · 2014 to 2018
$1.5M
Hopkins Clinical Center for Pulmonary Vascular Disease Phenomics ProgramU01HL125175 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI HASSOUN, PAUL M., MATHAI, STEPHEN C · 2015 to 2019
$1.1M
Peripheral Limitations in Pulmonary Hypertension and Effects of Muscle TrainingK23HL164901 · NHLBI · MAYO CLINIC ROCHESTER · PI Yogesh Nellore Vilambi Reddy · 2023 to 2026
backgroundPatients with lung disease, sleep apnea, and chronic thromboemboli can develop pulmonary hypertension, currently classified as group 3 or 4. Many of these patients also have risk factors for heart failure with preserved ejection fraction (HFpEF), but the optimal approach to identify the disease overlap remains unclear.
methodsPretest probability for HFpEF was determined using the HFpEF-ABA (age, body mass index, atrial fibrillation) algorithm among adjudicated group 3 or 4 patients at risk for pulmonary hypertension in the PVDOMICS study (Redefining Pulmonary Hypertension Through Pulmonary Vascular Disease Phenomics). Patients were stratified by current resting right heart catheterization criteria, and in a separate analysis, stratified only by HFpEF-ABA probability into low (<25%), intermediate, and high (≥75%) HFpEF probability groups.
resultsAmong 598 patients with group 3 disease, 27% (n=161) had elevated pulmonary capillary wedge pressure (PCWP) with postcapillary pulmonary hypertension even at rest, which was associated with the highest exercise PCWP. However, regardless of this resting PCWP-based classification, a larger subset had intermediate-to-high HFpEF-ABA probabilities (32% [n=197] high and 57% [n=358] intermediate HFpEF probability). High HFpEF probability in group 3 disease was associated with higher resting and dynamic PCWP response to NO, fluid, and exercise (
conclusionsQuantifying pretest probability for HFpEF in patients with sleep apnea, lung disease, or chronic thromboemboli identifies a progressive gradient for dynamic PCWP abnormalities with worse functional status and quality of life. These subclinical left heart abnormalities are not universally detectable by resting right heart catheterization alone and call for further study of whether strategies to prevent or treat HFpEF might improve functional status in these patients with high risk of occult HFpEF.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Left Heart Abnormalities in Patients With Lung Disease, OSA, and Chronic Thromboemboli at Risk for or With Known Pulmonary Hypertension. · full record | OpenQuestion